Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | OXTR | P30559 | 7/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1336911 | 0.99 | NPC1 (0.58) | NPC1RAB9AGPR55MEN1KMT2A | |
| SCHEMBL16059596 | 0.90 | NPC1 (0.59) | NPC1RAB9AGPR55MEN1KMT2A | |
| SCHEMBL3566149 | 0.84 | MAPT (0.53) | MEN1KMT2AOXTRAVPR1AGAA | |
| SCHEMBL14276865 | 0.80 | NPC1 (0.50) | NPC1RAB9AGPR55MEN1KMT2A | |
| SCHEMBL3626959 | 0.75 | POLB (0.47) | OXTRAVPR1AGAAPOLB | |
| SCHEMBL25379372 | 0.73 | OXTR (0.54) | MEN1KMT2AOXTRAVPR1AGAA | |
| SCHEMBL20776699 | 0.72 | OXTR (0.53) | MEN1KMT2AOXTRAVPR1A | |
| SCHEMBL335041 | 0.70 | KMT2A (0.50) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL8320959 | 0.70 | SMN1; SMN2 (0.49) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL334445 | 0.70 | MEN1 (0.50) | MEN1KMT2AALDH1A1LMNAOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | claimed |
| WO-2009147216-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009147216-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | GPR119, GLP1R, ADIPOR1 | NPC1 2854/4885RAB9A 4619/4885GPR55 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.